Triamcinolone acetonide nasal
Generic name
Triamcinolone acetonide nasal
Brand name
ATC Code
R01AD11
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
Cl and Vd in children 2 to 5 years is approximately 50% of that in adults.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Allergic rhinitis |
|---|
|
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Growth retardation.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Growth retardation: If long-term chronic use of nasal corticosteroids in children is necessary, give the lowest possible dose. Growth retardation in children has been reported with the use of therapeutic doses of nasal triamcinolone; with long-term use, check height regularly, especially with combined inhalation therapy for asthma. In case of growth inhibition, try to reduce the dose. Consider referral to a pediatrician, especially in children < 6 years.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Sympathomimetics, plain | ||
|---|---|---|
| R01AA08 | ||
| R01AA05 | ||
| R01AA09 | ||
| R01AA07 | ||
| Sympathomimetics, combinations excl. corticosteroids | ||
|---|---|---|
| R01AB01 | ||
| Antiallergic agents, excl. corticosteroids | ||
|---|---|---|
| R01AC03 | ||
| R01AC01 | ||
| R01AC02 | ||
| Corticosteroids | ||
|---|---|---|
| R01AD58 | ||
| R01AD01 | ||
| R01AD05 | ||
| R01AD08 | ||
| R01AD12 | ||
| R01AD12 | ||
| R01AD09 | ||
| R01AD59 | ||
| Other nasal preparations | ||
|---|---|---|
| R01AX10 | ||
| OTHER NASAL PREPARATIONS | ||
|---|---|---|
| R01AX10 | ||
Reference
- Genzyme Europe B.V., SmPC Nasacort (RVG 21837) 18-12-2020, www.geneesmiddeleninformatiebank.nl
Changes
Therapeutic Drug Monitoring
Overdose
